AN2 Therapeutics

ANTX · NASDAQ

$3.56+$0.19 (+5.64%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.37

Latest news

Press releaseOct 20, 4:13 PM ETBusiness Wire
AN2 Therapeutics to Participate at Upcoming Investor Conferences
Press releaseOct 12, 8:50 AM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
Press releaseSep 28, 7:00 AM ETBusiness Wire
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
Press releaseSep 16, 5:33 PM ETBusiness Wire
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
Press releaseAug 31, 6:00 PM ETBusiness Wire
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Press releaseAug 24, 7:00 AM ETBusiness Wire
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
Press releaseAug 11, 4:00 PM ETBusiness Wire
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
Press releaseJul 20, 10:30 AM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
NewsJun 24, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseJun 4, 7:00 AM ETBusiness Wire
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
Press releaseMay 21, 7:00 AM ETBusiness Wire
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Press releaseMay 11, 4:01 PM ETBusiness Wire
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
Press releaseMay 7, 4:01 PM ETBusiness Wire
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Press releaseMar 31, 7:00 AM ETBusiness Wire
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
Press releaseMar 17, 4:00 PM ETBusiness Wire
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
NewsMar 11, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsMar 11, 9:52 AM ETVandana Singh
AN2 Therapeutics Stock Cools Off After 90% Rally
Press releaseMar 9, 7:00 AM ETBusiness Wire
AN2 Therapeutics Announces $40 Million Private Placement Financing
NewsMar 6, 4:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsMar 6, 12:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
Press releaseMar 3, 4:00 PM ETBusiness Wire
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
Press releaseFeb 17, 7:00 AM ETBusiness Wire
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
Press releaseJan 12, 7:00 AM ETBusiness Wire
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
Press releaseNov 12, 4:01 PM ETBusiness Wire
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Press releaseNov 10, 7:00 AM ETBusiness Wire
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
Press releaseNov 6, 5:03 PM ETBusiness Wire
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
NewsSep 23, 5:07 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseAug 12, 4:01 PM ETBusiness Wire
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Press releaseAug 12, 7:00 AM ETBusiness Wire
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
Press releaseJul 23, 7:00 AM ETBusiness Wire
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
Press releaseJun 30, 7:00 AM ETBusiness Wire
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
NewsMay 1, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsOct 3, 5:24 AM ETAvi Kapoor
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
NewsAug 9, 2:38 PM ETAvi Kapoor
Crude Oil Rises; Blend Labs Shares Jump Following Q2 Results
NewsAug 9, 12:29 PM ETAvi Kapoor
US Stocks Edge Lower; EchoStar Shares Tumble After Q2 Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

AN2 Therapeutics to Participate at Upcoming Investor Conferences

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

12 Health Care Stocks Moving In Wednesday's Intraday Session

AN2 Therapeutics Stock Cools Off After 90% Rally

AN2 Therapeutics Announces $40 Million Private Placement Financing

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Friday's Intraday Session

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

12 Health Care Stocks Moving In Tuesday's After-Market Session

AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

12 Health Care Stocks Moving In Thursday's After-Market Session

Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket

Crude Oil Rises; Blend Labs Shares Jump Following Q2 Results

US Stocks Edge Lower; EchoStar Shares Tumble After Q2 Results